Northern Trust Corp Gain Therapeutics, Inc. Transaction History
Northern Trust Corp
- $690 Billion
- Q4 2024
A detailed history of Northern Trust Corp transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 84,586 shares of GANX stock, worth $230,919. This represents 0.0% of its overall portfolio holdings.
Number of Shares
84,586
Previous 44,944
88.2%
Holding current value
$230,919
Previous $80,000
115.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding GANX
# of Institutions
27Shares Held
2.77MCall Options Held
0Put Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.61 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.55 Million0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$730,0590.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA177KShares$483,4140.0% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny158KShares$431,7630.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $32.4M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...